129 related articles for article (PubMed ID: 6538593)
1. Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide.
Senn HJ; Glaus A; Bachmann-Mettler I
J Clin Oncol; 1984 Apr; 2(4):320-2. PubMed ID: 6538593
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
3. Lack of antiemetic effect of high-dose metoclopramide.
Roemeling RV; Christiansen NP; Hrushesky WJ
J Clin Oncol; 1985 Sep; 3(9):1273-6. PubMed ID: 4040959
[TBL] [Abstract][Full Text] [Related]
4. [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone].
Senn HJ; Köhler M; Glaus A; Bachmann-Mettler I; Weigand W
Dtsch Med Wochenschr; 1986 Jan; 111(4):129-35. PubMed ID: 3510848
[TBL] [Abstract][Full Text] [Related]
5. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
6. Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.
Strum SB; McDermed JE; Opfell RW; Riech LP
JAMA; 1982 May; 247(19):2683-6. PubMed ID: 7043002
[TBL] [Abstract][Full Text] [Related]
7. Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis.
Roila F; Basurto C; Bracarda S; Sassi M; Lupattelli M; Picciafuoco M; Boschetti E; Tonato M; Del Favero A
Eur J Cancer; 1991; 27(2):119-21. PubMed ID: 1827271
[TBL] [Abstract][Full Text] [Related]
8. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
9. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.
McDermed JE; Cohen JL; Joseph C; Strum SB
J Clin Oncol; 1985 Oct; 3(10):1400-8. PubMed ID: 3900303
[TBL] [Abstract][Full Text] [Related]
11. [Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial].
Fujii M; Kiura K; Kamei H; Okabe K; Toki H
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2257-61. PubMed ID: 3300561
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ethanol as an antiemetic in patients receiving cisplatin.
Spiess JL; Adelstein DJ; Hines JD
Clin Ther; 1987; 9(4):400-4. PubMed ID: 3607821
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
14. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Warrington PS; Allan SG; Cornbleet MA; MacPherson JS; Smyth JF; Leonard RC
Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1334-7. PubMed ID: 3790968
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
González Barón M; Chacón JI; García Girón C; Ordóñez Gallego A; García de Paredes ML; Feliu J; Zamora P; Herranz C; Garrido P; Artal A
Acta Oncol; 1991; 30(5):623-7. PubMed ID: 1892680
[TBL] [Abstract][Full Text] [Related]
17. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
[TBL] [Abstract][Full Text] [Related]
19. High dose metoclopramide as an antiemetic for patients receiving chemotherapy with cis-platinum.
Daniels M; Belt RJ
Oncol Nurs Forum; 1982; 9(3):20-2. PubMed ID: 6921788
[No Abstract] [Full Text] [Related]
20. Antiemetic efficacy of high-dose corticosteroids and droperidol in cisplatin-induced emesis: a controlled trial with droperidol and metoclopramide.
Donovitz GS; O'Quinn AG; Smith ML
Gynecol Oncol; 1984 Jul; 18(3):320-5. PubMed ID: 6540222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
